Pacific Biosciences (PACB) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
For the quarter ended December 2023, Pacific Biosciences of California (PACB) reported revenue of $58.36 million, up 113.4% over the same period last year. EPS came in at -$0.27, compared to -$0.35 in the year-ago quarter.
The reported revenue represents a surprise of +0.20% over the Zacks Consensus Estimate of $58.24 million. With the consensus EPS estimate being -$0.31, the EPS surprise was +12.90%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Pacific Biosciences performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenue- Product- Instrument: $35.10 million compared to the $33.17 million average estimate based on four analysts. The reported number represents a change of +475.4% year over year.
Revenue- Service and other: $4.36 million compared to the $4.02 million average estimate based on four analysts. The reported number represents a change of -4.9% year over year.
Revenue- Product: $54 million compared to the $50.75 million average estimate based on four analysts. The reported number represents a change of +137.2% year over year.
Revenue- Product- Consumable: $18.90 million compared to the $17.58 million average estimate based on four analysts. The reported number represents a change of +13.2% year over year.
View all Key Company Metrics for Pacific Biosciences here>>>
Shares of Pacific Biosciences have returned +6.4% over the past month versus the Zacks S&P 500 composite's +4.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pacific Biosciences of California, Inc. (PACB) : Free Stock Analysis Report
